A practical reference on derivatization: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-23. Anything still debated is marked as such rather than presented as settled.
Glutathione serves as a cofactor for several enzymes, including glutathione peroxidase and glutathione S-transferase. These enzymes help reduce hydrogen peroxide and lipid peroxides, and they conjugate reactive electrophiles for excretion. The molecule also acts as a reservoir for cysteine, an amino acid that is prone to oxidation. In addition, glutathione participates in the metabolism of nitric oxide, leukotrienes, and prostaglandins. Its roles extend to cell signaling, apoptosis, and the regulation of protein function through S-glutathionylation.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine, and it is the most abundant non-protein thiol in most living cells. The reduced form, GSH, carries a sulfhydryl group that can donate electrons, while the oxidized form, GSSG, forms when two GSH molecules link via a disulfide bond. The balance between these two forms helps define the cellular redox environment, and their ratio is often used as an indicator of oxidative stress. Because the sulfhydryl group is reactive, glutathione participates in many cellular processes, including detoxification and protein regulation.
Commercial glutathione is produced by microbial fermentation or chemical synthesis, then purified. Reduced and oxidized grades are offered separately, with purity specifications often exceeding 98 percent. The compound appears in foods such as fresh fruits, vegetables, and meats, although cooking and processing can lower amounts. Oral, topical, and inhaled forms are discussed in research and consumer contexts, but absorption and tissue delivery remain active areas of study. Regulatory status varies by country and intended use.
Glutathione is a small sulfur-containing peptide built from glutamic acid, cysteine, and glycine. Its distinctive feature is a gamma-glutamyl bond between glutamate's side-chain carboxyl group and cysteine's amino group. This linkage resists ordinary peptidases and helps the molecule remain stable inside cells. The reduced thiol form, often abbreviated GSH, is the dominant intracellular species. The oxidized disulfide dimer, GSSG, forms when two reduced molecules link through their cysteine sulfur atoms. The balance between these forms is a common redox indicator.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C10H17N3O6S | Reduced form (GSH) |
| Molar mass | 307.32 g/mol | For GSH; GSSG is 612.63 g/mol |
| Appearance | White crystalline powder | Usually lyophilized |
| Solubility in water | Freely soluble (≥100 mg/mL) | pH dependent |
| Typical storage | -20 °C, desiccated | Protect from light and oxygen |
Storage recommendations for glutathione reagents usually specify a cool, dry, dark environment because the thiol oxidizes in air and light. Solid material is often kept desiccated at low temperature, while solutions are prepared fresh or stored frozen in aliquots. Repeated freeze-thaw cycles can accelerate degradation, and metal ions can catalyze oxidation. Quality control may include purity assays, water content, and identity confirmation. Stability limits are method-specific, so a stated shelf life applies only to defined conditions and packaging.
Laboratory measurement of glutathione requires attention to oxidation before analysis. Blood, tissue, or cell samples can lose reduced glutathione as it converts to GSSG or forms mixed disulfides with proteins. Acid extraction, rapid freezing, and thiol-blocking reagents are common strategies to preserve the original distribution. Reported concentrations therefore depend on collection protocol, extraction method, and the time between sampling and analysis. Comparisons across studies are most reliable when these pre-analytical variables are described.
Common analytical approaches include enzymatic recycling assays, high-performance liquid chromatography, and mass spectrometry. The enzymatic recycling assay uses glutathione reductase and a colorimetric or fluorometric reagent to amplify signal, which gives good sensitivity for total glutathione. Chromatographic methods can separate GSH from GSSG and related thiols, while mass spectrometry offers structural confirmation and multiplexing. Each approach has different requirements for calibration, internal standards, and validation. No single method captures every form of glutathione in every matrix.
For solid glutathione reagents, storage at low temperature and protection from moisture and light are typical precautions. Aqueous solutions can oxidize over time, and pH affects stability; alkaline conditions generally promote thiol oxidation. Some protocols prepare fresh solutions, while others use antioxidants or chelators to limit metal-catalyzed oxidation. Purity and counterion content can vary among commercial preparations, affecting concentration calculations. Certificates of analysis and validated assays help verify identity and purity.
Measuring glutathione in biological samples requires attention to oxidation, because GSH can convert to GSSG after sample collection. Blood and plasma samples are often treated with acid or alkylating agents to preserve the reduced form. Without stabilization, apparent GSH concentrations can fall while GSSG rises. Differences in sample type, handling delay, and deproteinization method can produce results that are not comparable across studies. Reporting preanalytical details is therefore important for interpreting findings.
Common analytical approaches include enzymatic recycling assays, high-performance liquid chromatography, and mass spectrometry. Enzymatic recycling measures total glutathione after converting GSSG back to GSH, while separation methods can quantify GSH and GSSG separately. Derivatization may be used to improve detection or stability during analysis. LC-MS/MS offers high specificity and can distinguish glutathione from related thiols and adducts. Each method has different sensitivity, throughput, and susceptibility to interference, so method selection depends on the study question and sample matrix.
Quality control for glutathione materials checks identity, assay, purity, water content, and disulfide content. Commercial products vary from research-grade powder to dietary supplements, and labels may not distinguish reduced from oxidized forms. In the United States, oral glutathione is commonly sold as a dietary supplement rather than an approved drug, while injectable forms fall under different rules and may require a prescription. Regulatory status differs by country. Analytical certificates, when available, help verify what a material contains, but independent testing remains important for interpretation.
Laboratory measurement of glutathione typically starts with rapid acid extraction to prevent oxidation and enzymatic degradation. Common methods include enzymatic recycling assays, high-performance liquid chromatography, and liquid chromatography coupled with mass spectrometry. The recycling assay uses glutathione reductase and a thiol-reactive colorimetric or fluorescent reagent, measuring total glutathione after converting disulfide forms. Chromatographic methods can separate reduced and oxidized forms, which helps when the redox ratio is the target. Choice of method affects sensitivity, specificity, and the amount of sample needed.
Samples for glutathione analysis require careful handling because the compound oxidizes readily and can be consumed by enzymes after collection. Blood is often treated with acid or thiol-blocking agents soon after draw, and plasma should be separated quickly from red blood cells. Tissues are usually snap-frozen or extracted immediately. Aqueous solutions of glutathione are less stable than dry powder and degrade faster at neutral or alkaline pH, in light, or with dissolved oxygen. Repeated freeze-thaw cycles also reduce reliability.
Glutathione is most stable as a dry powder stored cool and dry, but its thiol group is readily oxidized in solution. Aqueous preparations at neutral or alkaline pH lose GSH faster because the thiolate form reacts with dissolved oxygen and metal ions. Acidic conditions, chelating agents, and oxygen exclusion can slow oxidation, while repeated freeze-thaw cycles promote degradation. Light exposure and trace metals also contribute to loss. Laboratories typically validate stability for their own matrices because degradation rates depend on pH, temperature, concentration, and container materials.
Commercial glutathione is available in research-grade, food-grade, and supplement-grade forms, and purity specifications differ accordingly. Certificates of analysis commonly report identity by nuclear magnetic resonance or mass spectrometry, purity by HPLC, residual solvents, and heavy metals. Reference standards with assigned purity support calibration, while isotopically labeled glutathione can serve as an internal standard for mass spectrometry. For supplements, label claims may not be independently verified, and regulatory oversight varies by country. Verification often involves third-party testing for identity, potency, and contaminants.
Quantifying glutathione requires distinguishing GSH from GSSG and preventing oxidation during sample preparation. Common approaches include the enzymatic recycling assay, often called the Tietze method, which measures total glutathione after converting GSSG to GSH. HPLC with ultraviolet or fluorescence detection and LC-MS/MS can separate and quantify both forms, sometimes after derivatization of the thiol group. Blood, plasma, and tissue samples differ in matrix and baseline concentrations, so method validation must account for recovery, linearity, and interference. No single assay is universally standard.
Asilomar conference on recombinant DNA Genetic engineering Genetically modified organism Recombinant virus Vector DNA Biomolecular engineering Recombinant DNA technology Host cell protein T7 expression system
== Examples == All monosaccharides are reducing sugars because they either have an aldehyde group (if they are aldoses) or can tautomerize in solution to form an aldehyde group (if they are ketoses). This includes common monosaccharides like galactose, glucose, glyceraldehyde, fructose, ribose, and xylose. Many disaccharides, like cellobiose, lactose, and maltose, also have a reducing form, as one of the two units may have an open-chain form with an aldehyde group. However, sucrose and trehalose, in which the anomeric carbon atoms of the two units are linked together, are nonreducing disaccharides since neither of the rings is capable of opening.
A wide gap exists between developed and developing countries' 3G and 4G cellular coverage, and issues such as dropped calls, delays, and weak signals hamper telecommunications efficacy in rural areas. Even when countries overcome infrastructural challenges, the price of network connectivity can exclude smallholders, poor farmers, and those in remote areas. Similar accessibility and affordability issues exist for digital devices and digital accounts. According to a 2016 GSMA report, of the 750 million-plus farmers in the 69 surveyed countries, about 295 million had a mobile phone; only 13 million had both a mobile phone and a mobile money account. Despite lingering gaps in network coverage, ICT access has skyrocketed in recent years. In 2007, only 1% of people in developing countries used Internet, but by 2015, 40% did. Mobile-broadband subscriptions, which increased thirty-fold between 2005 and 2015, drove much of this growth. As a key enabler of agricultural change, digital infrastructure requires further development, but growing ICT access indicates progress.
Proteasome inhibitors have effective anti-tumor activity in cell culture, inducing apoptosis by disrupting the regulated degradation of pro-growth cell cycle proteins. This approach of selectively inducing apoptosis in tumor cells has proven effective in animal models and human trials. Lactacystin, a natural product synthesized by Streptomyces bacteria, was the first non-peptidic proteasome inhibitor discovered and is widely used as a research tool in biochemistry and cell biology. Lactacystin was licensed to Myogenics/Proscript, which was acquired by Millennium Pharmaceuticals, now part of Takeda Pharmaceuticals. Lactacystin covalently modifies the amino-terminal threonine of catalytic β subunits of the proteasome, particularly the β5 subunit responsible for the proteasome's chymotrypsin-like activity. This discovery helped to establish the proteasome as a mechanistically novel class of protease: an amino-terminal threonine protease. Bortezomib (Boronated MG132), a molecule developed by Millennium Pharmaceuticals and marketed as Velcade, is the first proteasome inhibitor to reach clinical use as a chemotherapy agent. Bortezomib is used in the treatment of multiple myeloma. Notably, multiple myeloma has been observed to result in increased proteasome-derived peptide levels in blood serum that decrease to normal levels in response to successful chemotherapy. Studies in animals have indicated that bortezomib may also have clinically significant effects in pancreatic cancer.
== Diagnosis == Diagnostic criteria for Type 5 diabetes are under development. In the spring of 2025, the International Diabetes Federation (IDF) tasked a working group, which includes Meredith Hawkins, a professor of medicine at Albert Einstein College of Medicine in The Bronx, New York, with developing official diagnostic and therapeutic guidelines for Type 5 diabetes.
Sources: en.wikipedia.org
=== Amino acid transport deficiency and neurotransmitter synthesis impairment === Amino acid transport deficiency and neurotransmitter synthesis impairment are significant concerns in individuals with maple syrup urine disease. Reduced levels of amino acids such as glutamate, phenylalanine, tyrosine, tryptophan, methionine, and alanine in the central nervous system have been shown to affect learning, memory, emotional behavior (including major depressive and anxiety disorders), ADHD, OCD, and movement disorders In a normal physiological state, large neutral amino acids (LNAA) are transferred from the blood to the brain via the large amino acid transporter (LAT1/SLC7A5) at the blood-brain barrier. However, increased plasma levels and higher affinity of leucine may saturate LAT1, thereby competitively preventing the transportation of other amino acids, resulting in lower concentrations within the brain. Amino acids such as isoleucine, valine, threonine, methionine, glutamine, tyrosine, phenylalanine, tryptophan, and histidine are particularly affected. Methionine, a precursor for S-adenosylmethionine, is essential for one-carbon metabolism in the brain, while other LAT1-transported amino acids are involved in the synthesis of neurotransmitters, including histamine, serotonin, dopamine, and norepinephrine. Increased plasma concentrations of branched-chain keto acids (BCKA) are transported through the blood–brain barrier via the monocarboxylate transporter (MCT/SLC16A1). Elevated levels of alpha-ketoisocaproate (α-KIC) result in a reduction in glutamate, glutamine, and GABA.
Portal venous systems A portal venous system is a series of veins or venules that directly connect two capillary beds. The two systems in verebrates are the hepatic portal system, and the hypophyseal portal system.
== Genetics == AGAT deficiency is caused by deficient activity of arginine:glycine amidinotransferase, which is coded for by GATM, located on the long arm of chromosome 15. AGAT deficiency is inherited in an autosomal recessive manner, which means pathogenic variants must be inherited from each parent. This enzyme catalyzes the first step in creatine biosynthesis, the combination of arginine and glycine to form guanidinoacetate, which also results in the formation or ornithine as a by product. These reactions take place primarily in the kidney and pancreas. The clinical manifestations of AGAT deficiency are caused by the decreased amounts of creatine produced.
16,000, 19 September 2007- The SENSEX on 19 September 2007 crossed the 16,000 mark, closing at a historic peak of 16,322. The bull hits because of the rate cut of 50 bit/s in the discount rate by the Fed chief Ben Bernanke. 17,000, 26 September 2007- On 26 September 2007, the SENSEX crossed the 17,000 mark for the first time, creating a record for the second fastest 1000 point gain in just 5 trading sessions. It failed however to sustain the momentum and closed below 17,000. The SENSEX closed above 17,000 for the first time on the following day. Reliance group has been the main contributor in this bull run, contributing 256 points. This also helped Mukesh Ambani's net worth to grow to over ₹2 lakh crore ($50 billion). It was also during this record bull run that the SENSEX for the first time zoomed ahead of the Nikkei of Japan.
Chronic consumption of paracetamol is in many cases not of benefit, and may result in abnormal liver function tests, and higher doses may lead to toxicity, including liver failure. Paracetamol poisoning is one of the leading causes of poisoning in high-income countries, and the foremost cause of acute liver failure in many countries. Paracetamol was first made in 1878 by Harmon Northrop Morse or possibly in 1852 by Charles Frédéric Gerhardt. It is the most commonly used medication for pain and fever in both the United States and Europe. It is on the World Health Organization's List of Essential Medicines. Paracetamol is available as a generic medication, with brand names including Tylenol and Panadol, among others. In 2023, it was the 112th most commonly prescribed medication in the United States, with more than 5 million prescriptions.
Sources: en.wikipedia.org
Affinity label for the tRNA binding sites on the E. coli ribosome allowed the identification of A and P site proteins most likely associated with the peptidyltransferase activity; labelled proteins are L27, L14, L15, L16, L2; at least L27 is located at the donor site, as shown by E. Collatz and A.P. Czernilofsky. Additional research has demonstrated that the S1 and S21 proteins, in association with the 3′-end of 16S ribosomal RNA, are involved in the initiation of translation.
=== Gingival crevicular fluid as a biomarker source === For research purposes, utilisation of GCF (gingival crevicular fluid) or PISF (peri-implant sulcular fluid) have been proven to be reliable indicators to examine gingival health, though this is rarely done in clinical practice. Through saliva samples obtained from individuals, the GCF/PISF mixed within saliva have been studied for the level of cytokines and inflammatory mediators. Examples of these mediators include Interleukin (IL) 1-ß, IL-6, macrophage chemotactic protein, interferon g-induced protein 10 (IP-10) and vascular endothelial growth factor (VEGF). Results indicate that individuals with periodontal disease have a significant increase in cytokine count compared to individuals who are of good gingival health. This is explained to be due to the increased interaction between the bacterial biofilm and the cells of the periodontal tissue, leading to heightened diffusion of these mediators along with the GCF into the gingival sulcus.
== History == The earliest description of a lectin is believed to have been given by Peter Hermann Stillmark in his doctoral thesis presented in 1888 to the Imperial University of Dorpat. Stillmark isolated ricin, an extremely toxic hemagglutinin, from seeds of the castor plant (Ricinus communis). Although lectins were first discovered in plants, they are now known to be present throughout nature. The first lectin to be purified on a large scale and available on a commercial basis was concanavalin A, which is now the most-used lectin for characterization and purification of sugar-containing molecules and cellular structures. The legume lectins are probably the most well-studied lectins. Long before a deeper understanding of their numerous biological functions was developed, the plant lectins, also known as phytohemagglutinins, were noted for their particularly high specificity for foreign glycoconjugates (e.g., those of fungi and animals) and used in biomedicine for blood cell testing and in biochemistry for fractionation.
The first documented use of electrical stimulation for pain relief dates back to 46 AD when Scribonius Largus of the ancient Roman Empire used the electric properties of torpedo fish to relieve headaches. Scientific studies of neuromodulation began in 1745, when German physician De Haen published "a number of cases of spasmodic, paralytic and other nervous affections cured by electricity". The first implementation of electrocutical apparatus in hospital medical treatment recorded in Middlesex Hospital of London in 1767. In 1780, Italian physicist and biologist Luigi Galvani investigated how electrical signals in nerves could control muscle movement, further evidence of the electrical nature of the neuronal activity.
=== Neuromodulation === Neuromodulation is the second-oldest and third-largest department of Medtronic. Its products include neurostimulation systems and implantable drug delivery systems for chronic pain, common movement disorders, and urologic and gastrointestinal disorders. The department's revenues in 2014 amounted to $1.9 billion, or 11% of Medtronic's total revenues.
Sources: en.wikipedia.org
Glutathione is a tripeptide of three amino acids: glutamate, cysteine, and glycine. The cysteine residue provides the sulfhydryl group that gives the molecule its reducing properties.
GSH is the reduced form, which contains a free sulfhydryl group. GSSG is the oxidized form, formed when two GSH molecules join through a disulfide bond. The ratio of GSH to GSSG is often used to assess cellular redox status.
No, glutathione is synthesized endogenously in most cells. It is not classified as an essential nutrient because the body can produce it from amino acid precursors. Dietary sources exist, but they are not required to maintain life.
It is a tripeptide rather than a full protein. Proteins generally contain many amino acids joined by alpha-peptide bonds, while glutathione has three residues and an unusual gamma-glutamyl linkage. That structure affects how enzymes recognize and break it down.